XORTX Therapeutics (XRTX) Other Non Operating Income (2020 - 2026)
XORTX Therapeutics (XRTX) posted Other Non Operating Income of $6190.0 for Q1 2026, up 615.61% on a QoQ basis from $865.0 in Q4 2025, and up 1609.94% year-over-year from $362.0 in Q1 2025.
XORTX Therapeutics (XRTX) Other Non Operating Income (2020 - 2026) Analysis & Trends
XORTX Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $6190.0 for Q1 2026.
- Quarterly Other Non Operating Income rose 1609.94% year-over-year to $6190.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1501.0 (up 102.5% YoY) and the FY2025 annual result came in at -$4327.0, up 94.07% from the prior year.
- Other Non Operating Income was $6190.0 for Q1 2026 at XORTX Therapeutics, up from $865.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $461447.9 in Q4 2022 and bottomed at -$389399.0 in Q3 2022.
- A 5-year average of -$5311.5 and a median of $362.0 in 2025 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 40353.73% in 2022, while the deepest fall reached 3904.04% in 2022.
- XORTX Therapeutics' Other Non Operating Income stood at $461447.9 in 2022, then tumbled by 98.47% to $7062.6 in 2023, then tumbled by 911.83% to -$57336.0 in 2024, then jumped by 101.51% to $865.0 in 2025, then soared by 615.61% to $6190.0 in 2026.
- Business Quant data shows XRTX's Other Non Operating Income at $6190.0 in Q1 2026, $865.0 in Q4 2025, and -$16473.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,190.00 |
| Dec 31, 2025 | 865.00 |
| Sep 30, 2025 | -16,473.00 |
| Jun 30, 2025 | 10,919.00 |
| Mar 31, 2025 | 362.00 |
| Dec 31, 2024 | -57,336.00 |
| Sep 30, 2024 | 14,715.00 |
| Jun 30, 2024 | -17,744.00 |
| Mar 31, 2024 | -12,644.00 |
| Dec 31, 2023 | 7,062.56 |
| Sep 30, 2023 | -3,668.00 |
| Jun 30, 2023 | 2,601.12 |
| Mar 31, 2023 | -6,255.61 |
| Dec 31, 2022 | 461,447.88 |
| Sep 30, 2022 | -389,398.98 |
| Jun 30, 2022 | -214,022.25 |
| Mar 31, 2022 | 123,083.16 |
| Dec 31, 2021 | 275,062.31 |
| Sep 30, 2021 | -9,725.16 |
| Jun 30, 2021 | 7,336.00 |